Acera Surgical Names Former Orthofix, Boston Scientific Exec Michael Finegan as CEO

Acera Surgical, a company developing synthetic materials for regenerative medical applications, has appointed Michael Finegan as its new CEO, effective immediately. Former co-CEOs Agnès Rey-Giraud and Jake Wilson will stay on as board members.
 
“Mike joins as the right person at the right time to lead Acera,” Rey-Giraud, founder of the company, told the press. “Acera is poised to move into a phase of dramatic growth with the increasing success of our product portfolio, both current and future. With CMS granting Restrata its own product code for use as a synthetic skin substitute, all wound care sites of service are now open to Acera.”
 
Finegan said, “Acera has the potential to become the market leader in synthetic wound repair, and I’m confident that the company’s next few years will see extraordinary success. I’m thrilled to be joining the company at this exciting time and honored to be joining a team of dedicated, caring employees who work every day to improve the health of patients facing serious medical conditions.”
 
Prior to launching a medical device and technology company consultancy in 2021, Finegan spent 14 years at Orthofix, seven of which were as the company’s chief strategy officer. Before his stint at Orthofix, Finegan served over 16 years at Boston Scientific, including VP of corporate sales and VP of national accounts.
 
Wilson said, “Mike is well-known and well-respected in the industry. He excels at aligning his teams with strategic development goals and creating a culture of innovation, disciplined growth and rigorous attention to market needs. At the same time, Mike’s focus never wavers from the patients’ well-being that he and his teams serve.”